Sorbinil
Star0
Identification
- Generic Name
- Sorbinil
- DrugBank Accession Number
- DB02712
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental, Investigational
- Structure
- Weight
- Average: 236.1992
Monoisotopic: 236.059720369 - Chemical Formula
- C11H9FN2O3
- Synonyms
- Sorbinil
- sorbinilo
- Sorbinilum
- External IDs
- CP-45,634
- CP-45634
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UAldose reductase inhibitorHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as hydantoins. These are heterocyclic compounds containing an imidazolidine substituted by ketone group at positions 2 and 4.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Azolidines
- Sub Class
- Imidazolidines
- Direct Parent
- Hydantoins
- Alternative Parents
- 1-benzopyrans / Alpha amino acids and derivatives / 5-monosubstituted hydantoins / Alkyl aryl ethers / N-acyl ureas / Aryl fluorides / Benzenoids / Dicarboximides / Azacyclic compounds / Oxacyclic compounds show 6 more
- Substituents
- 1-benzopyran / 5-monosubstituted hydantoin / Alkyl aryl ether / Alpha-amino acid or derivatives / Aromatic heteropolycyclic compound / Aryl fluoride / Aryl halide / Azacycle / Benzenoid / Benzopyran show 20 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- organofluorine compound, imidazolidinone, azaspiro compound, chromanes, oxaspiro compound (CHEBI:102029)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- G4186B906P
- CAS number
- 68367-52-2
- InChI Key
- LXANPKRCLVQAOG-NSHDSACASA-N
- InChI
- InChI=1S/C11H9FN2O3/c12-6-1-2-8-7(5-6)11(3-4-17-8)9(15)13-10(16)14-11/h1-2,5H,3-4H2,(H2,13,14,15,16)/t11-/m0/s1
- IUPAC Name
- (4S)-6-fluoro-2,3-dihydrospiro[1-benzopyran-4,4'-imidazolidine]-2',5'-dione
- SMILES
- FC1=CC=C2OCC[C@]3(NC(=O)NC3=O)C2=C1
References
- Synthesis Reference
Berkeley W. Cue, Jr., Philip D. Hammen, Stephen S. Massett, "Regeneration of 6-fluoro-4-chromanone from by-products in the synthesis of sorbinil." U.S. Patent US4431828, issued August, 1981.
US4431828- General References
- Not Available
- External Links
- PubChem Compound
- 337359
- PubChem Substance
- 46504981
- ChemSpider
- 298991
- BindingDB
- 16312
- ChEBI
- 102029
- ChEMBL
- CHEMBL266497
- ZINC
- ZINC000000002070
- Therapeutic Targets Database
- DCL000270
- PDBe Ligand
- SBI
- Wikipedia
- Sorbinil
- PDB Entries
- 1ah0 / 2pdk / 4ga8
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Diabetes Mellitus / Diabetic Retinopathy (DR) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source logP 0.78 HANSCH,C ET AL. (1995) - Predicted Properties
Property Value Source Water Solubility 2.63 mg/mL ALOGPS logP 0.59 ALOGPS logP 0.44 Chemaxon logS -2 ALOGPS pKa (Strongest Acidic) 8.67 Chemaxon pKa (Strongest Basic) -4.9 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 67.43 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 54.94 m3·mol-1 Chemaxon Polarizability 20.84 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9841 Blood Brain Barrier + 0.8909 Caco-2 permeable - 0.6021 P-glycoprotein substrate Substrate 0.765 P-glycoprotein inhibitor I Non-inhibitor 0.8602 P-glycoprotein inhibitor II Non-inhibitor 1.0 Renal organic cation transporter Non-inhibitor 0.8178 CYP450 2C9 substrate Non-substrate 0.8326 CYP450 2D6 substrate Non-substrate 0.7526 CYP450 3A4 substrate Non-substrate 0.5179 CYP450 1A2 substrate Non-inhibitor 0.6004 CYP450 2C9 inhibitor Non-inhibitor 0.6738 CYP450 2D6 inhibitor Non-inhibitor 0.8405 CYP450 2C19 inhibitor Non-inhibitor 0.5509 CYP450 3A4 inhibitor Non-inhibitor 0.9654 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8779 Ames test Non AMES toxic 0.6783 Carcinogenicity Non-carcinogens 0.9121 Biodegradation Not ready biodegradable 0.9854 Rat acute toxicity 2.3697 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9473 hERG inhibition (predictor II) Non-inhibitor 0.7417
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. DetailsAldose reductase
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Glyceraldehyde oxidoreductase activity
- Specific Function
- Catalyzes the NADPH-dependent reduction of a wide variety of carbonyl-containing compounds to their corresponding alcohols with a broad range of catalytic efficiencies.
- Gene Name
- AKR1B1
- Uniprot ID
- P15121
- Uniprot Name
- Aldose reductase
- Molecular Weight
- 35853.125 Da
References
Drug created at June 13, 2005 13:24 / Updated at February 21, 2021 18:51